EndoVascular Aneurysm Repair: Heart Remodeling and Aortic Stiffness Study (EVAR-HRAS)

July 20, 2026 updated by: Ines Drenjancevic, Josip Juraj Strossmayer University of Osijek

Impact of Endovascular Abdominal Aortic Aneurysm Repair on Aortic Stiffness and Left Ventricular Remodeling

Abdominal aortic aneurysm (AAA) is associated with a high burden of cardiovascular morbidity and mortality. Although endovascular aneurysm repair (EVAR) has become the preferred treatment for many patients with infrarenal AAA because of its lower perioperative risk, its impact on arterial stiffness and cardiac function remains insufficiently understood. Experimental and clinical evidence suggests that endograft implantation may increase aortic stiffness by reducing aortic compliance, potentially altering ventricular-arterial coupling and contributing to left ventricular remodeling and dysfunction.

This prospective observational study aims to evaluate the effects of elective EVAR on aortic stiffness, left ventricular structure and function, and circulating biomarkers of myocardial stress and extracellular matrix remodeling. Patients with infrarenal AAA scheduled for elective EVAR will be assessed before the procedure and at 48 hours, 6 months, and 12 months after intervention. Aortic stiffness will be assessed using estimated carotid-femoral pulse wave velocity (cfPWV), while left ventricular function and remodeling will be evaluated by transthoracic echocardiography, including global longitudinal strain (GLS). Circulating NT-proBNP and MMP-3 concentrations will also be measured.

The study will provide insight into the cardiovascular effects of EVAR and may improve understanding of procedure-related changes in arterial stiffness and cardiac remodeling, thereby supporting better long-term cardiovascular risk assessment and postoperative management in patients undergoing EVAR.

Study Overview

Status

Enrolling by invitation

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Osijek, Croatia, 31000
        • Department of Vascular Surgery, University Hospital Center Osijek

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients with abdominal aortic aneurysm (AAA) scheduled for elective endovascular aneurysm repair (EVAR) will be prospectively enrolled. The study population will include patients undergoing standard-of-care EVAR, who will be followed longitudinally to assess changes in arterial stiffness, cardiac function, and circulating biomarkers before and after the procedure.

Description

Inclusion Criteria:

  • Adult patients (≥18 years of age) with diagnosed abdominal aortic aneurysm (AAA) who are scheduled for elective endovascular aneurysm repair (EVAR)
  • Patients eligible for EVAR according to current clinical guidelines and anatomical criteria
  • Signed informed consent for participation in the study
  • Ability to undergo scheduled follow-up examinations (baseline, early post-procedural assessment, and follow-up visits)

Exclusion Criteria:

  • Emergency EVAR for ruptured or symptomatic abdominal aortic aneurysm
  • Previous aortic repair or previous endovascular intervention involving the abdominal aorta
  • Concomitant major cardiovascular surgery or intervention during the study period
  • Severe hemodynamic instability or critical illness at the time of inclusion
  • Active infection or acute inflammatory disease that may influence vascular or inflammatory biomarkers
  • Malignancy with active treatment or life expectancy limiting follow-up
  • Inability to provide informed consent
  • Inability to complete planned follow-up assessments
  • Known severe valvular heart disease or advanced heart failure
  • Conditions affecting arterial stiffness measurements (e.g. atrial fibrillation, severe arrhythmias, inability to obtain reliable PWV measurements)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
EVAR patients
Patients undergoing endovascular aneurysm repair (EVAR) with assessment of arterial stiffness and cardiac function before the procedure and during follow-up (2 days, 6 months, and 12 months after EVAR).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in arterial stiffness after endovascular aneurysm repair (EVAR)
Time Frame: Baseline (pre-EVAR) to 12 months after EVAR (2 days, 6 months, 12 months)
Change in arterial stiffness after endovascular aneurysm repair (EVAR)
Baseline (pre-EVAR) to 12 months after EVAR (2 days, 6 months, 12 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Early and long-term changes in arterial stiffness after EVAR
Time Frame: Baseline, 2 days, 6 months, 12 months
Changes in PWV at 2 days, 6 months, and 12 months after EVAR compared with baseline.
Baseline, 2 days, 6 months, 12 months
Changes in cardiac function after EVAR
Time Frame: Baseline, 2 days, 6 months, 12 months
Changes in echocardiographic parameters of cardiac structure and function (LVEF, E/e', LA volume, LV volume, LA strain, LV strain etc.) following EVAR.
Baseline, 2 days, 6 months, 12 months
Changes in circulating biomarkers after EVAR
Time Frame: Baseline, 2 days, 6 months, 12 months
Changes in circulating biomarkers associated with vascular function, inflammation, and cardiovascular risk after EVAR.
Baseline, 2 days, 6 months, 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Ana Stupin, MD, PhD, Faculty of Medicine Osijek

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

June 30, 2029

Study Registration Dates

First Submitted

July 20, 2026

First Submitted That Met QC Criteria

July 20, 2026

First Posted (Actual)

July 23, 2026

Study Record Updates

Last Update Posted (Actual)

July 23, 2026

Last Update Submitted That Met QC Criteria

July 20, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Abdominal Aortic Aneurysm

Subscribe